ストックスクリーナーアプリを入手
760.27
0.36%
-2.77
プレマーケット:
767.00
6.73
+0.89%
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (REGN) Movement - Stock Traders Daily
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker - Benzinga
Monoclonal Antibody Therapeutics (Mabs) Market (2026-2033) | - openPR.com
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals - simplywall.st
Surprises Report: What are the future prospects of Regeneron Pharmaceuticals IncWeekly Market Outlook & Smart Swing Trading Techniques - baoquankhu1.vn
Targets Report: Is Regeneron Pharmaceuticals Inc gaining market shareQuarterly Earnings Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval - finance.yahoo.com
FDA approves expanded EYLEA HD dosing intervals - Eyes On Eyecare
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy - finance.yahoo.com
Regeneron And TriNetX Partner To Expand Global Genomic And EHR Linked Data Platform - BioPharma APAC
Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC - MarketBeat
2,145 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Perpetual Ltd - MarketBeat
Regeneron’s EYLEA HD Label Update Shifts Retinal Care And Competition - simplywall.st
Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock - MSN
REGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regeneron Pharmaceuticals Inc (REGN) SEC filings - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals - National Today
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists - finance.yahoo.com
Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc - GuruFocus
Regeneron (REGN) director Ryan sells $77,727 in stock By Investing.com - Investing.com South Africa
Regeneron Pharmaceuticals Inc (RGO.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron (REGN) director Ryan sells $77,727 in stock - Investing.com
Small Rule 10b5-1 sale by Regeneron (REGN) director Arthur F. Ryan - Stock Titan
Best Pharmaceutical Stocks To Follow TodayApril 3rd - MarketBeat
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance Australia
Regeneron Secures Two FDA Approvals in One Day: Does the Math Support an Above $1,200 Target? - TIKR.com
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation - FinancialContent
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In JapanLearn Why - simplywall.st
Aberdeen Group Boosts Regeneron Pharmaceuticals Holdings - National Today
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD - VisionMonday.com
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - finance.yahoo.com
FDA approves extended dosing for Regeneron’s EYLEA HD treatment By Investing.com - Investing.com Australia
Regeneron partners with TriNetX for health data access - Investing.com
Regeneron Pharmaceuticals announced that, as part of their strategic partnership, the company will invest up to 200 million dollars in Trinetx. - Bitget
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN34.SA) company profile and facts - Yahoo Finance Singapore
Regeneron says it expects to avoid new US pharma tariffs - Reuters
FDA Expands Dosing Flexibility for Regeneron's EYLEA HD - GuruFocus
FDA approves extended dosing for Regeneron’s EYLEA HD treatment - Investing.com
FDA lets some EYLEA HD patients cut eye injections to 2 or 3 a year - stocktitan.net
Ophthalmology Drugs Market: Current Landscape and Future Outlook - Barchart
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $825 - Moomoo
Moody Lynn & Lieberson LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron’s Cat Allergy Blocker is Back and Reducing Itchy Eyes - Allergic Living
AVIP BlackRock Balanced Allocation Portfolio's Regeneron Pharmaceuticals Inc(REGN) Holding History - GuruFocus
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
BMO Autocallable Notes Linked to Regeneron (NASDAQ: REGN) — US$270K - Stock Titan
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid - finance.yahoo.com
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment - The Globe and Mail
0.56%
2.30%
大文字化:
|
ボリューム (24 時間):